These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26781267)

  • 1. Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer.
    Jensen LH
    Expert Opin Investig Drugs; 2016; 25(3):359-65. PubMed ID: 26781267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New developments in systemic therapy for advanced biliary tract cancer.
    Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
    Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
    Gautschi O; Mach N; Rothschild SI; Li Q; Stahel RA; Zippelius A; Cathomas R; Früh M; Betticher DC; Peters S; Rauch D; Feilchenfeldt J; Bubendorf L; Savic S; Jaggi R; Leibundgut EO; Largiadèr C; Brutsche M; Pilop C; Stalder L; Pless M; Ochsenbein AF;
    Clin Lung Cancer; 2015 Sep; 16(5):358-65. PubMed ID: 25843489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy for biliary tract cancers.
    Faris JE; Zhu AX
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):326-36. PubMed ID: 22318523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biliary-tract cancer: improving therapy by adding molecularly targeted agents.
    Jensen LH
    Lancet Oncol; 2012 Feb; 13(2):118-9. PubMed ID: 22192730
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.
    Philip PA; Lutz MP
    Pancreas; 2015 Oct; 44(7):1046-52. PubMed ID: 26355547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Therapy in Biliary Tract Cancers.
    Merla A; Liu KG; Rajdev L
    Curr Treat Options Oncol; 2015 Oct; 16(10):48. PubMed ID: 26266637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
    J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to a combination of erlotinib and bevacizumab therapy after immune checkpoint inhibitor.
    Okauchi S; Miyazaki K; Yamada H; Satoh H
    Clin Respir J; 2020 May; 14(5):500-501. PubMed ID: 31925931
    [No Abstract]   [Full Text] [Related]  

  • 13. Emerging treatment with systemic chemotherapy and targeted agents for biliary cancers.
    Boku N
    Curr Opin Investig Drugs; 2010 Jun; 11(6):653-60. PubMed ID: 20496260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
    J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
    Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of erlotinib in patients with advanced biliary cancer.
    Philip PA; Mahoney MR; Allmer C; Thomas J; Pitot HC; Kim G; Donehower RC; Fitch T; Picus J; Erlichman C
    J Clin Oncol; 2006 Jul; 24(19):3069-74. PubMed ID: 16809731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging molecular target antagonists for the treatment of biliary tract cancer.
    Lombardi P; Marino D; Fenocchio E; Chilà G; Aglietta M; Leone F
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):63-75. PubMed ID: 29468924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
    Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
    Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
    Sandler A
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.